Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 80.40% is 557% above its 5-year average of 12.24%, near the high end of its 5-year range (-1941.81%–92.70%).
58.42% above its 12-month average of 50.75%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 25.13%.
GROSS MARGIN
80.40%
GROSS MARGIN AVG TTM
50.75%
GROSS MARGIN AVG 3Y
38.23%
GROSS MARGIN AVG 5Y
12.24%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+58.42%
CURRENT VS 3Y AVG
+110.32%
CURRENT VS 5Y AVG
+556.65%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
40.82%
median of 781 covered companies
CURRENT VS SECTOR MEDIAN
+96.96%
vs the sector median at left
Market Cap
$2.37M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$2.31M
Gross Margin
63.43%
TTM Avg
61.72%
3Y Avg
62.82%
5Y Avg
60.98%
Market Cap
$2.45M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$2.25M
Gross Margin
-628.02%
TTM Avg
-265.21%
3Y Avg
-2905.33%
5Y Avg
-2576.02%
Market Cap
$2.54M
Gross Margin
23.21%
TTM Avg
29.65%
3Y Avg
45.21%
5Y Avg
30.14%
Market Cap
$2.54M
Gross Margin
67.21%
TTM Avg
75.24%
3Y Avg
78.18%
5Y Avg
70.66%
Market Cap
$2.54M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Onconetix, Inc. (ONCO) | $2.38M | 80.40% | 50.75% | 38.23% | 12.24% |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH)vs › | $2.37M | 0.00% | 0.00% | 0.00% | 0.00% |
| Creative Medical Technology Holdings, Inc. (CELZ)vs › | $2.31M | 63.43% | 61.72% | 62.82% | 60.98% |
| Moleculin Biotech, Inc. (MBRX)vs › | $2.45M | 0.00% | 0.00% | 0.00% | 0.00% |
| GeoVax Labs, Inc. (GOVX)vs › | $2.25M | -628.02% | -265.21% | -2905.33% | -2576.02% |
| bioAffinity Technologies, Inc. (BIAF)vs › | $2.54M | 23.21% | 29.65% | 45.21% | 30.14% |
| Jaguar Health, Inc. (JAGX)vs › | $2.54M | 67.21% | 75.24% | 78.18% | 70.66% |
| FibroBiologics, Inc. Common Stock (FBLG)vs › | $2.54M | 0.00% | 0.00% | 0.00% | 0.00% |
| Nuwellis, Inc. (NUWE)vs › | $2.61M | 69.69% | 64.31% | 60.13% | 58.62% |
| iSpecimen Inc. (ISPC)vs › | $2.67M | 1.25% | 22.09% | 37.48% | 43.16% |
Gross Margin
80.4%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 25.13% |
| 2026-03-31 | -7.71% |
| 2025-12-31 | 81.58% |
| 2025-09-30 | 88.55% |
| 2025-06-30 | 66.20% |
| 2025-03-31 | 45.10% |
| 2024-12-31 | 92.70% |
| 2024-09-30 | 25.91% |
| 2024-06-30 | 14.29% |
| 2024-03-31 | 26.98% |
| 2023-12-31 | -1941.81% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | 0.00% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-03-31 | 0.00% |
